Navigation Links
London Genetics Focuses on Partnering Following Successful Pharmacogenetics Conference
Date:10/30/2009

LONDON, October 30 /PRNewswire/ -- London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, has entered an intensive partnering programme following on from its successful pharmacogenetic conference in September(1). The meeting recognised that while pharmacogenetics and genetics have great potential in helping the biopharmaceutical industry overcome its many challenges, early clinical collaboration between companies, academia, regulators and payers is now needed.

The company will over the coming months be attending several conferences in the UK, Europe and the US to highlight its pharmacogenetics expertise. These include in November Bio-Europe 2009 (Vienna)(2), the 5th Annual Burrill Personalised Medicine Meeting (San Francisco)(3), and the International Congress on Genetics and Genomics at the American Heart Association meeting (Orlando)(4), and in December, Genesis 2009 (London)(5).

Pharmacogenetics is the study of how our genetic make-up affects the way in which we metabolise and respond to drugs. As a result, it is expected to play a key role in the future of drug development and healthcare delivery as the industry faces increasing pressure to replenish its pipeline and improve drug safety. By combining its access to genetic expertise with strategic advice on the application of pharmacogenetics in drug development, London Genetics can help companies meet this need for smarter and more efficient drug development. Given the genetic resources of its founding partners, London Genetics has broad therapeutic experience with a focus on cardiovascular drugs and cardiovascular safety.

The London Genetics Pharmacogenetics Conference 'Harnessing Genetic Knowledge To Improve Clinical Development and Patient Care', was attended by biopharmaceutical industry executives, as well as academics, regulatory experts and leading geneticists. Debates and conclusions from t
'/>"/>

SOURCE London Genetics Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. PRA International: Participating Sponsor for Exploratory Clinical Development World in London
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Genetics Determine Optimal Drug Dose of Common Anticoagulant
5. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
6. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
7. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
8. ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar(R)
9. deCODE Obesity Study Sheds Light on How Genetics Affects Risk and Onset of Common Diseases
10. Genzyme Genetics Announces Launch of Carrier Testing and Prenatal Diagnosis for Spinal Muscular Atrophy
11. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Advanced Drug Delivery Systems -- Focus on ... STUDY OBJECTIVES A ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
(Date:1/14/2014)... InformEx, North America,s leading business ... hold the 30 th edition of its annual conference ... from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... chemical and specialty chemical companies will take part in the ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... 15 , - Nine-Month Sales (Excluding Technical ... EBITDA Margin at High Level of 17.2% , ... In the first nine months of the financial ... (prior year EUR 783.4m).,Excluding the Technical Plastics business which has been sold, ...
... Minn., Oct. 14 AbbeyMoor Medical Inc. ... CPT code by the American Medical Association (AMA) for ... action, effective in January 2010, upgrades The Spanner from ... Category I procedure code for established procedures. This major ...
Cached Medicine Technology:Gerresheimer has Passed the Turning Point 2Gerresheimer has Passed the Turning Point 3Gerresheimer has Passed the Turning Point 4AbbeyMoor Medical Receives Category I CPT(R) Code for The Spanner(TM) Prostatic Stent Procedure 2AbbeyMoor Medical Receives Category I CPT(R) Code for The Spanner(TM) Prostatic Stent Procedure 3
(Date:7/10/2014)... Huddersfield could help to improve the quality of some ... as butter, mayonnaise, yoghurt and fruit drinks and ... her work. , Katerina gained her MSc degree in ... she has embarked on research for a PhD. ... investigating the potential of carbohydrates extracted from the pods ...
(Date:7/10/2014)... review identifying the clinical indicators most strongly associated with ... of developing evidence-based guidelines for concussion diagnosis, prognosis, and ... Neurosurgery , official journal of the ... published by Lippincott Williams & Wilkins , a ... , Based on analysis of the best available research ...
(Date:7/10/2014)... For decades, health-conscious people around the globe have ... figuring this was one of the paths to good ... clinical trials of antioxidant supplements have repeatedly dashed the ... their cancer risk. Virtually all such trials have ... In fact, in several trials antioxidant supplementation has been ...
(Date:7/10/2014)... Researchers at sarcomas research group at the Bellvitge Biomedical ... (ICO) have been tested in 19 patients a new ... results, which indicate that the new treatment could stabilize ... week in the British Journal of Cancer ., ... tumor and complex since there are several subtypes. It ...
(Date:7/10/2014)... that a new drug could prove useful in treating small ... cancer. , Scientists from the Cancer Research UK Manchester Institute, ... Manchester Cancer Research Centre, teamed up with experts at AstraZeneca, ... a drug known as AZD3965 - on small cell ... Clinical Cancer Research , also helps identify which patients ...
Breaking Medicine News(10 mins):Health News:World interest in research work on the benefits of the Okra plant 2Health News:What's a concussion? Review identifies four evidence-based indicators 2Health News:What's a concussion? Review identifies four evidence-based indicators 3Health News:How antioxidants can accelerate cancers, and why they don't protect against them 2Health News:New therapeutic combination to slow resistant sarcomas 2Health News:New drug active against most aggressive type of lung cancer cells 2
... June 18 Roxane Laboratories, Inc.,announced today ... Application (ANDA),for Ramipril Capsules, 1.25mg, 2.5mg, 5mg ... Administration. The 1.25mg, 2.5mg, 5mg and 10mg ... Roxane Laboratories Ramipril,Capsules are available for immediate ...
... cancer who had abundant vitamin D in their blood were ... who were deficient in the vitamin, according to a new ... of the study -- the first to examine the effect ... research, but it is too early to recommend supplements as ...
... a human patient,s cloned infection-fighting T cells as the sole ... A team led by Cassian Yee, M.D., an associate member ... Center, reports these findings in the June 19 issue of ... and colleagues removed CD4+ T cells, a type of white ...
... Authority continues monitoring and evaluating wrong-site surgeries,with ... wrong-site surgery,update, HARRISBURG, Pa., June 18 ... "National Time Out Day," which is a,national ... time out" before every,operation to confirm correct ...
... DENVER, June 18 Air Methods Corporation,(Nasdaq: ... in the,world, announced today that Chief Executive Officer ... present at the Jefferies 2nd Annual,Healthcare Conference in ... at 11:15,a.m. ET., Interested parties can listen ...
... in Indiana to propose awareness-raising ... legislation in 2009., ... of July as Indiana Safe Haven Month and the,National Safe Haven ... for babies who were adopted thanks to legislation,passed overwhelmingly in the ...
Cached Medicine News:Health News:Roxane Laboratories, Inc. Announces the Launch of Ramipril Capsules 2Health News:Study links vitamin D to colon cancer survival 2Health News:Patient's own infection-fighting T cells put late-stage melanoma into long-term remission 2Health News:Patient Safety Authority Supports 'National Time Out Day' 2Health News:Governor and Lt. Governor Celebrate Eight Years of Safe Haven Babies 2
Clearview RSV is a simple, immunochromatographic assay to aid in the diagnosis of respiratory syncytial virus (RSV) infections in children less than 6 years and adults over age 60....
Clearview ULTRA FOB is a rapid, two-step immunochemical test for the detection of fecal occult blood....
... RTVue is an ultra-high speed, high resolution ... for retina imaging and analysis. ... Fourier-Domain Optical Coherence technology just emerging from ... The ultra-high speed and high ...
The Clearview hCG Test is for the rapid detection of human chorionic gonadotropin (hCG) in urine specimens. This test kit is used to obtain a visual, qualitative result and is intended for professio...
Medicine Products: